Design Highlights
- The GLP-1 Bridge program launches on July 1, 2026, providing temporary access to Eli Lilly’s weight-loss medications.
- Eligible beneficiaries include those over 18 with a BMI of 35 or higher, or 30-35 with specific comorbidities.
- The program offers a flat copayment of $50 per month, improving affordability for participants.
- Covered medications include Eli Lilly’s Foundayo and Wegovy, available at a reduced net price of approximately $245 monthly.
- Eligibility is limited, with analysts estimating only about 10% of Medicare beneficiaries will qualify for the program.
In a surprising twist, Medicare is rolling out its GLP-1 Bridge program, set to kick off on July 1, 2026. Yes, you heard that right. The Centers for Medicare & Medicaid Services (CMS) is stepping into the weight-loss game, but only temporarily. This program is here to provide access to certain weight-loss medications, and it’ll stick around until December 31, 2027. Initially, it was supposed to end a year earlier, but apparently, they decided we needed more time to test the waters. Recent polling shows that 56% of GLP-1 users say drugs were difficult to afford, highlighting the need for such initiatives.
Medicare’s GLP-1 Bridge program launches July 1, 2026, offering temporary access to weight-loss meds until December 31, 2027.
Eligibility? Well, it’s not as simple as just being overweight. To get in on this deal, you must be enrolled in a Medicare Part D plan or similar. And you better meet some strict criteria. If you’re over 18 and have a Body Mass Index (BMI) of 35 or higher, congratulations—you’re halfway there. But if you’re between 30 and 35, good luck. You need some health issues in tow, like heart failure or Stage 3a kidney disease. Just don’t have type 2 diabetes or sleep apnea, or you’re out. It’s a bit of a gauntlet, really. Analysts estimate that strict clinical criteria will limit eligibility to roughly 10% of Medicare beneficiaries nationwide.
What’s on the menu? Eli Lilly’s Foundayo and Wegovy, both injectable and oral, are the star players. You’ll also see Zepbound’s KwikPen making an appearance. But if you thought you could snag other GLP-1 drugs, think again. Only the ones for weight loss are up for grabs. Manufacturers are playing ball, offering these medications at a reduced net price of about $245 a month. Not bad, eh? Additionally, these drugs will be provided outside Medicare Part D coverage and payment flow.
Now, here’s the kicker: eligible beneficiaries will only pay a flat $50 copayment for a month’s supply. That’s right—$50, no matter how much cash you’ve got in your pocket. But don’t get too excited; that payment won’t count toward your Medicare drug plan deductible. And if you need refills? No need for a new approval.
